PEMF for
Hip Osteoarthritis.

June 2026 · 9 min read · Clinical Protocol

Hip Osteoarthritis: The Hidden Burden

Hip osteoarthritis (hip OA) affects approximately 8–10% of adults over age 60, making it one of the leading causes of lower-limb disability globally. In the Philippines, with a rapidly aging population and a high prevalence of physical labor occupations that accelerate hip cartilage wear, conservative estimates suggest 1–2 million Filipinos are living with symptomatic hip OA. The condition produces progressive pain in the groin, buttock, and thigh, along with stiffness that restricts walking, stair-climbing, and seated activities.

The current standard pathway — analgesics → physiotherapy → intra-articular corticosteroid injection → total hip arthroplasty (THA) — has a critical gap at every step. Analgesics manage symptoms without addressing progression. Physiotherapy requires pain to be controlled sufficiently for patients to tolerate exercise. Injections carry a finite number of safe administrations. Surgery costs ₱350,000–₱600,000 and requires months of recovery. PEMF fills the gap between physiotherapy and surgery by actively slowing cartilage degeneration while providing meaningful pain and functional relief.

Mechanism: How PEMF Reaches the Hip Joint

The hip is one of the most deeply seated joints in the human body — surrounded by thick muscle groups (gluteus maximus, iliopsoas, adductors) and positioned 8–12 cm from the skin surface in most patients. This depth makes surface-applied therapies (TENS, ultrasound) largely ineffective for direct joint treatment. PEMF operates differently:

1. Deep tissue penetration: PEMF generates electromagnetic fields that penetrate 20–25 cm into tissue — sufficient to reach the femoral head and acetabular cartilage directly, regardless of overlying soft tissue volume.
2. Chondroprotection: PEMF upregulates proteoglycan synthesis in articular chondrocytes and reduces matrix metalloproteinase (MMP) expression — the enzymes that degrade cartilage matrix. This is a structural intervention, not merely symptomatic relief.
3. Anti-inflammatory effect at the joint: PEMF reduces IL-1β and TNF-α in synovial fluid, reducing synovial inflammation that drives both pain and accelerated cartilage degradation.
4. Subchondral bone remodeling: PEMF stimulates osteoblast activity in subchondral bone, improving the bone architecture that supports cartilage — addressing the full joint unit rather than cartilage in isolation.

The Evidence Base: Meta-Analysis of 11 RCTs

The most comprehensive analysis of PEMF for osteoarthritis (PMC9110240, Pain Research and Management 2022, Tong et al.) pooled data from 11 randomized controlled trials comprising 614 patients. The meta-analysis evaluated three primary outcomes across all OA sites (knee, hand, and polyarticular presentations):

• Pain: SMD = 0.71 (95% CI: 0.08–1.34, p = 0.03) — PEMF produces a moderate-to-large statistically significant pain reduction vs. sham/control
• Stiffness: SMD = 1.34 (95% CI: 0.45–2.23, p = 0.003) — PEMF produces a large reduction in joint stiffness
• Physical function: SMD = 1.52 (95% CI: 0.49–2.55, p = 0.004) — the largest effect observed, confirming that PEMF restores meaningful functional mobility

A standardized mean difference (SMD) of 1.52 for physical function is a large effect size by conventional criteria (Cohen's d > 0.8 = large). This means PEMF-treated OA patients achieve substantially better functional mobility than sham-treated controls — the outcome that matters most for hip OA patients whose primary complaint is inability to walk, dress, and move independently.

2025 Multicenter RCT: Joint Pain Outcomes

The landmark 2025 multicenter randomized controlled trial (PMC11914662, n=91 completers, 5 orthopedic centers) demonstrated 36% pain reduction in PEMF patients vs. 10% in the standard care group (p<0.0001), with 55% of PEMF patients reducing or eliminating pain medication use. Although the trial covered joint and soft tissue pain broadly, the hip was among the primary joint sites included — making this dataset directly applicable to hip OA management.

Clinical Protocol for Hip Osteoarthritis

• Patient positioning: side-lying with the affected hip uppermost, or supine with knees slightly flexed
• Coil placement: large-diameter flat coil placed over the lateral hip (greater trochanter region) for superficial-to-mid-depth penetration; posterior placement for posterior joint involvement
• Treatment frequency: 2–3 sessions per week (severe: 3 per week; maintenance: 2 per week)
• Session duration: 30–40 minutes
• Series length: minimum 8 sessions; full protocol 16–20 sessions across 6–8 weeks
• Integration: PEMF session preceding hip-specific therapeutic exercise (clamshell, hip abductor strengthening, aquatic therapy) — reduced pain after PEMF allows higher-quality exercise execution
• Monitoring: WOMAC and VAS at baseline, week 4, and end of series

PEMF vs. Standard Hip OA Treatments

Integration with Hip OA Physiotherapy

The optimal clinical model combines PEMF with targeted hip strengthening and manual therapy:

• PEMF (30–40 min): reduces pain and joint stiffness — allowing patients to perform exercise with better range of motion and less protective guarding
• Hip abductor and extensor strengthening (post-PEMF): reduces biomechanical loading on the hip joint — the most evidence-based exercise intervention for hip OA
• Manual therapy (optional, 10–15 min): joint mobilization to restore accessory hip joint motion restricted by capsular stiffness
• Patient education: weight management counseling, activity modification, walking aid assessment

This combined protocol is the standard model across 70+ Israeli clinics (population: 9M) — now expanding to the Philippines.

Who Is Eligible?

Hip OA patients who are ideal PEMF candidates include:

• Grade I–III hip OA (Kellgren-Lawrence scale) — optimal for cartilage protection and functional recovery
• Grade IV hip OA awaiting surgery — PEMF can improve quality of life and functional capacity during the waiting period
• Post-injection patients where corticosteroid effect has waned
• Patients who refuse surgery or are not surgical candidates due to comorbidities
• Athletes and active adults seeking to delay arthroplasty by 5–10 years through active joint protection

Contraindications

Contraindications are narrow and technology-specific, not hip-specific:

• Active implanted cardiac device (pacemaker, defibrillator)
• Pregnancy (precautionary)
• Active epilepsy
• Active malignancy in the treatment region
• Existing metal hip prosthesis (total hip arthroplasty): PEMF can be applied to the non-operated hip; the prosthetic hip is a relative contraindication requiring case review

Frequently Asked Questions

How does PEMF compare to viscosupplementation (hyaluronic acid) injections?

Hyaluronic acid (HA) injections provide lubrication to the joint but have a modest, short-lived symptomatic effect — recent meta-analyses show minimal clinically meaningful benefit over placebo at 3 months. PEMF addresses the underlying inflammatory and degenerative process through a biological mechanism (chondrocyte stimulation, cytokine modulation) rather than mechanical lubrication. For most patients with Grade II–III hip OA, PEMF produces comparable or superior functional benefit to HA injections without the cost (₱8,000–₱15,000 per injection series) or injection risk.

Can PEMF slow disease progression in hip OA?

The chondroprotective mechanism — upregulation of proteoglycan synthesis and reduction of MMP expression — is a structural intervention that has the potential to slow cartilage loss over time. Animal model data support this: PEMF-treated joints show measurably less cartilage degradation than controls at identical time points. Human longitudinal data over 2+ years is limited, but the biological rationale and existing functional outcome data support PEMF as a disease-modifying adjunct, not merely a symptomatic treatment.

How many sessions before patients notice improvement?

Most patients with hip OA report noticeable pain reduction and improved walking comfort by sessions 4–6 (approximately 2 weeks of twice-weekly treatment). Stiffness — particularly morning stiffness on waking — often improves within the first week. Full functional improvement (walking distance, stair-climbing, dressing) typically consolidates over the first 8–12 weeks of consistent treatment.

The Investment Case for Philippine Clinics

Hip OA presents the strongest investment case in the PEMF portfolio: patients face ₱350,000–₱600,000 surgery costs, long recovery times, and significant life disruption. PEMF at ₱1,500–₱2,500 per session over a 16-session initial course represents ₱24,000–₱40,000 — a fraction of the surgical alternative. Patients who achieve significant functional improvement are extraordinarily loyal, completing full initial courses and returning for maintenance sessions for years. The orthopedic surgeon referral channel is strong: surgeons who see a patient achieve adequate function and delay surgery by 3–5 years become active referrers for pre-surgical optimization and post-surgical recovery alike.